ARICEPT ODT Rx
Generic Name and Formulations:
Donepezil HCl 5mg, 10mg; orally-disintegrating tabs.
Indications for ARICEPT ODT:
Tabs: Swallow whole with water. ODT: dissolve on tongue, follow with water. Mild-to-moderate: Initially 5mg daily at bedtime, may increase to max 10mg daily after 4–6 weeks; usual dose: 5mg or 10mg once daily. Moderate-to-severe: initially 5mg daily at bedtime, may increase to 10mg daily after 4–6 weeks; may further increase to max 23mg daily after 3 months; usual dose: 10mg or 23mg once daily.
Cardiac conduction conditions. Peptic ulcer. Monitor for GI bleeding. Seizures. Asthma or COPD. GU obstruction. Body weight <55kg. Pregnancy (Cat.C). Nursing mothers.
Reversible acetylcholinesterase inhibitor (piperidine deriv).
Drugs that affect CYP2D6 and CYP3A4 may affect rate of elimination. Antagonizes anticholinergics. May potentiate succinylcholine-type muscle relaxants, other cholinesterase inhibitors, cholinergic agonists (eg, bethanecol). Concomitant NSAIDs may increase risk of GI bleed.
Nausea, diarrhea, vomiting, insomnia, muscle cramps, fatigue, anorexia, weight loss (esp. using 23mg/day dose).
Tabs 5mg, 10mg—30, 90, 1000; 23mg—30, 90; ODT—30
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib
- Durvalumab Shows Overall Survival Benefit in Patients With Stage III NSCLC
- Baseline Thrombopoietin Levels May Help Predict Response to ITP Treatment
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed